Best GLP-1 Providers in Arizona (2026)

See by medication

Looking for a specific GLP-1? Browse Arizona providers by drug.

About GLP-1s in Arizona

Arizona has a robust telehealth framework that supports GLP-1 prescribing through online providers. AHCCCS (Arizona Medicaid) coverage of GLP-1s for obesity is limited and typically requires diabetes diagnosis.

• •Arizona's adult obesity rate is 31.3%
• •AHCCCS Medicaid coverage of GLP-1s is limited to diabetes
• •Phoenix is one of the largest telehealth markets in the Southwest

Top Cities for GLP-1 Treatment in Arizona

Telehealth providers ship to all Arizona addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Arizona GLP-1 clinic directory →

GLP-1 Care Access in Arizona: The Numbers

Arizona has 725 NPI-registered in-person weight-management clinics across 49 cities — 11 with an obesity-medicine taxonomy, 238 endocrinology, and 484 bariatric — alongside 102 telehealth programs that ship to Arizona addresses. The cheapest verified ongoing compounded semaglutide price available to Arizona residents is $65/mo (tirzepatide: $97/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Arizona

In Q1 2026, Arizona Medicaid reimbursed approximately $17,192,165 across 15,672 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Arizona cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $189/mo.

For the exact criteria, drug list, and appeal process, read our Arizona Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Arizona

According to CDC data, 31.3% of Arizona adults have obesity (BMI of 30 or higher). This places Arizona at #28 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Arizona residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions